Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity Publisher Pubmed



Hosseinzadeh R1 ; Feizisani F2 ; Shomali N3, 4, 5 ; Abdelbasset WK6, 7 ; Hemmatzadeh M3, 5 ; Gholizadeh Navashenaq J8 ; Jadidiniaragh F4, 5 ; Bokov DO9, 10 ; Janebifam M3 ; Mohammadi H11, 12
Authors

Source: IUBMB Life Published:2021


Abstract

Immune checkpoint blockade therapy (ICBT) has become a successful cancer treatment approach in the field of cancer immunotherapy. Blockade of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) with monoclonal antibodies have been known as successful examples of cancer immunotherapy in recent years. Although ICBT has been shown to be beneficial in cancers, such benefits have only been seen in a portion of cancer patients. In this regard, enhancing the therapeutic effects of inhibiting PD-1 and PD-L1 and reducing the side effects of this approach can be considered as a potential approach in a successful ICBT. In this review, we have highlighted new viewpoints regarding improving the therapeutic effect of PD-1 and PD-L1 blockades in cancer therapy. Besides, their expression levels as a biomarker with prognostic value, their role in intestinal microbiota modulation, combination therapy, and immune-related side effects (irAEs) have been discussed. © 2021 International Union of Biochemistry and Molecular Biology.
2. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
Experts (# of related papers)
Other Related Docs
4. Tumor Immunology, Clinical Immunology (2022)
10. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
15. Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer, International Archives of Allergy and Immunology (2022)